SystImmune

  • World

    Week In Review: SystImmune Out-Licenses Global Rights For ADC To BMS In $8.4B Deal

    ClaudioVentrella/iStock via Getty Images Deals and Financings SystImmune, the Seattle arm of Chengdu’s Biokin Pharma, out-licensed global rights (ex-China) for…

    Read More »
Back to top button